{
    "doi": "https://doi.org/10.1182/blood.V116.21.3879.3879",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1648",
    "start_url_page_num": 1648,
    "is_scraped": "1",
    "article_title": "Early Interim 18 f-FDG PET In Hodgkin's Lymphoma: Evaluation on 304 Patients ",
    "article_date": "November 19, 2010",
    "session_type": "Hodgkin Lymphoma - Biology, excluding Therapy: Poster II",
    "topics": [
        "fluorodeoxyglucose f18",
        "hodgkin's disease",
        "positron-emission tomography",
        "bleomycin/dacarbazine/doxorubicin/vinblastine protocol",
        "complete remission",
        "follow-up",
        "treatment failure"
    ],
    "author_names": [
        "Pier Luigi Zinzani, MD",
        "Luigi Rigacci",
        "Vittorio Stefoni",
        "Alessandro Broccoli",
        "Benedetta Puccini",
        "Letizia Gandolfi",
        "Stefano Fanti",
        "Antonio Castagnoli",
        "Cinzia Pellegrini",
        "Gian Carlo Montini",
        "Federica Quirini",
        "Giulia Antognoli",
        "Luca Vaggelli",
        "Enrico Derenzini",
        "Lisa Argnani",
        "Valentina Ambrosini",
        "Claudio Agostinelli",
        "Stefano A. Pileri, MD",
        "Alberto Bosi",
        "Michele Baccarani, MD"
    ],
    "author_affiliations": [
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Hematology Department, Azienda Ospedaliero Universitaria \u201cCareggi\u201d, Firenze, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Hematology Department, Azienda Ospedaliero Universitaria \u201cCareggi\u201d, Firenze, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Department of Nuclear Medicine, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Nuclear Medicine, Ospedale \u201cMisericordia e Dolce\u201d, Prato, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Department of Nuclear Medicine, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Hematology Department, Azienda Ospedaliero Universitaria \u201cCareggi\u201d, Firenze, Italy, "
        ],
        [
            "Nuclear Medicine, Azienda Ospedaliero Universitaria \u201cCareggi\u201d, Firenze, Italy"
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Department of Nuclear Medicine, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ],
        [
            "Hematology Department, Azienda Ospedaliero Universitaria \u201cCareggi\u201d, Firenze, Italy, "
        ],
        [
            "Institute of Hematology and Medical Oncology \u201cL. e A. Sera\u0300gnoli\u201d, Policlinico \u201cSant'Orsola-Malpighi\u201d, Bologna, Italy, "
        ]
    ],
    "first_author_latitude": "44.4912163",
    "first_author_longitude": "11.3615273",
    "abstract_text": "Abstract 3879 Purpose. The use of early ( interim ) positron emission tomography (PET) restaging during front-line therapy in Hodgkin's lymphoma (HL) has considerably increased in clinical practice as an early recognition of treatment failure allows patients to be addressed to more intensive treatment regimens. Patients and Methods. Between June 1997 and June 2009, 304 newly-diagnosed Hodgkin's lymphoma patients (147 early-stage and 157 advanced-stage) were treated with the ABVD regimen at two Italian institutions. Patients underwent to a PET staging and restaging at baseline, after 2 cycles of therapy and at the end of the treatment. Results. 53 patients showed a positive interim PET and only 13/53 (24.5%) achieved a complete response (CR), whereas 251 patients showed a negative PET and 231/251 (92%) remained in CR. Comparison between interim PET-positive and interim PET-negative patients indicated a significant association between PET findings and 9-year progression-free survival (p=0.0000) and 9-year overall survival (p=0.0000), with a median follow-up of 31 months. Among the early-stage patients, 19 had a positive interim PET and only 4 (21%) achieved a CR; among the 128 negative interim PET patients, 122 (97.6%) obtained a CR. In the advanced-stage subset, 34 patients showed a persistently positive PET (with only 9/34, 26.4% in CR), whereas 123 showed a negative interim PET, with 109 (88.6%) remaining in CR. Conclusions. Our results confirm the role of early PET as a significant step forward for the management of both early and advanced-stage HL patients, offering the potential for an immediate switch to high-dose treatments, if required. Disclosures: No relevant conflicts of interest to declare."
}